JapanStake
Pharmaceutical · Fiscal year end Mar 31

DAIICHI SANKYO COMPANY, LIMITED

4568

第一三共株式会社

FIGI BBG000BWPLT14568.T4568 JPCorp. no. 1010001095640

Latest half-year results

First half · fiscal year to 2026-03 · filed 2025-11-07

For the first half of the fiscal year to 2026-03: Revenue ¥975.4 billion (+10.5% YoY), Profit before tax ¥163.2 billion (-15.2% YoY), Net income ¥130.8 billion (-10.8% YoY).

This periodYear on year
Revenue¥975.4bn+10.5%
Profit before tax¥163.2bn-15.2%
Net profit to owners¥130.8bn-10.8%

From the securities report on EDINET, which states no forecast. History via /v1/companies/4568/earnings-releases.

Financials

IFRS · consolidated · fiscal year to 2026-03-31
Revenue
¥2.1tn
Net income
¥279.7bn
ROE
16.9%
Equity ratio
42.1%
Dividend / share
¥78
Employees
20,171
Revenue · ¥tn
FY2022: ¥1.0tn 1.04 FY2022FY2023: ¥1.3tn 1.28 FY2023FY2024: ¥1.6tn 1.6 FY2024FY2025: ¥1.9tn 1.89 FY2025FY2026: ¥2.1tn 2.12 FY2026
Net income · ¥bn
FY2022: ¥67.0bn 67 FY2022FY2023: ¥109.2bn 109 FY2023FY2024: ¥200.7bn 201 FY2024FY2025: ¥295.8bn 296 FY2025FY2026: ¥279.7bn 280 FY2026
Fiscal yearRevenueNet incomeTotal assetsNet assetsROEEPSOperating CF
2026-03-31¥2,123.0bn¥279.7bn¥3,996.3bn¥1,684.0bn16.9%¥151.17¥77.7bn
2025-03-31¥1,886.3bn¥295.8bn¥3,456.1bn¥1,623.4bn17.9%¥155.96¥53.8bn
2024-03-31¥1,601.7bn¥200.7bn¥3,461.1bn¥1,688.2bn12.8%¥104.69¥599.3bn
2023-03-31¥1,278.5bn¥109.2bn¥2,508.9bn¥1,445.9bn7.8%¥56.96¥114.5bn
2022-03-31¥1,044.9bn¥67.0bn¥2,221.4bn¥1,350.9bn5.1%¥34.94¥139.2bn

Indicators

Computed by us from filings · fiscal year to 2026-03-31
MetricValuePercentile among listed companies
ROE, %16.982.6
Ordinary margin0.137779.9
Equity ratio, %42.130
Revenue growth0.125575.5
Net income growth-0.054231.1
Operating cash flow / assets0.019423.2
Policy-uncertainty measure0.00 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.
Ownership activity 0 filer(s) stated they may make proposals in 365 days; 0 new 5% holder(s) in 180 days; net stake change +0.77pt in 90 days; 2.9% held by other listed companies.

Results wording balance: +0.46. Proprietary text method; it describes the wording only and does not interpret context.

Interest example: if all ¥300.5bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥1.5bn, 1.9% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.

Via /v1/companies/4568/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them
Bond ratings stated in filings: Moody's A2 (2026-10-02, 第11回無担保社債); R&I AA (2026-10-02, 第11回無担保社債). One bond's rating on that date, as the company stated it; it may have changed. The agencies' opinions, not ours. /v1/companies/4568/credit-ratings
Share buyback, report to —: ¥91.8bn acquired of a ¥200.0bn limit. /v1/companies/4568/buybacks
Internal control, 2026-06-19: see filing 上記の評価の結果、当事業年度末日時点において、当社の財務報告に係る内部統制は有効であると判断いたしました。 Filing

Segments, votes and tender offers

Stated in EDINET filings
Latest voting result: 2026-06-22 · 剰余金の処分の件 · passed. /v1/companies/4568/voting

Ownership changes

All companies →

Trades by 5% holders

From the 60-day trade tables in 5% reports
¥2,409¥2,689¥2,968 2021-12-072022-02-04 2022-02-04 · bought 3,676 @ ¥2,409 · Capital Research and Management Company2022-02-03 · bought 2,238 @ ¥2,468 · Capital Research and Management Company2022-02-02 · bought 7,684 @ ¥2,468 · Capital Research and Management Company2022-02-01 · bought 4,001 @ ¥2,588 · Capital Research and Management Company2022-01-31 · bought 1,142 @ ¥2,564 · Capital Research and Management Company2022-01-28 · bought 6,198 @ ¥2,483 · Capital Research and Management Company2022-01-27 · bought 2,415 @ ¥2,599 · Capital Research and Management Company2022-01-26 · bought 3,106 @ ¥2,616 · Capital Research and Management Company2022-01-25 · bought 7,624 @ ¥2,580 · Capital Research and Management Company2022-01-24 · bought 5,104 @ ¥2,606 · Capital Research and Management Company2022-01-21 · bought 5,244 @ ¥2,610 · Capital Research and Management Company2022-01-20 · bought 3,434 @ ¥2,581 · Capital Research and Management Company2022-01-19 · bought 8,160 @ ¥2,643 · Capital Research and Management Company2022-01-18 · bought 6,893 @ ¥2,673 · Capital Research and Management Company2022-01-14 · bought 9,478 @ ¥2,696 · Capital Research and Management Company2022-01-13 · sold 1,805 @ ¥2,725 · Capital Research and Management Company2022-01-12 · bought 1,861 @ ¥2,769 · Capital Research and Management Company2022-01-11 · bought 13,085 @ ¥2,696 · Capital Research and Management Company2022-01-10 · bought 7,337 @ ¥2,704 · Capital Research and Management Company2022-01-07 · bought 5,131 @ ¥2,734 · Capital Research and Management Company2022-01-06 · bought 4,996 @ ¥2,823 · Capital Research and Management Company2022-01-05 · sold 496 @ ¥2,949 · Capital Research and Management Company2022-01-04 · bought 8,538 @ ¥2,935 · Capital Research and Management Company2022-01-03 · bought 4,009 @ ¥2,934 · Capital Research and Management Company2021-12-31 · bought 3,549 @ ¥2,929 · Capital Research and Management Company2021-12-30 · sold 702 @ ¥2,929 · Capital Research and Management Company2021-12-29 · sold 532 @ ¥2,942 · Capital Research and Management Company2021-12-28 · bought 5,333 @ ¥2,968 · Capital Research and Management Company2021-12-27 · bought 2,637 @ ¥2,906 · Capital Research and Management Company2021-12-23 · sold 15 @ ¥2,927 · Capital Research and Management Company2021-12-22 · sold 1,503 @ ¥2,890 · Capital Research and Management Company2021-12-21 · bought 4,228 @ ¥2,835 · Capital Research and Management Company2021-12-20 · bought 3,403 @ ¥2,840 · Capital Research and Management Company2021-12-17 · sold 934 @ ¥2,916 · Capital Research and Management Company2021-12-16 · sold 2,920 @ ¥2,875 · Capital Research and Management Company2021-12-15 · bought 4,554 @ ¥2,876 · Capital Research and Management Company2021-12-14 · sold 3,794 @ ¥2,846 · Capital Research and Management Company2021-12-13 · sold 7,019 @ ¥2,857 · Capital Research and Management Company2021-12-10 · bought 342 @ ¥2,857 · Capital Research and Management Company2021-12-09 · bought 318 @ ¥2,842 · Capital Research and Management Company2021-12-08 · sold 2,022 @ ¥2,787 · Capital Research and Management Company2021-12-07 · sold 3,087 @ ¥2,726 · Capital Research and Management Company
Bought SoldHover a dot for the trade
HolderPeriodNet sharesNet % of sharesAvg. filed priceRange
Capital International Inc.2021-12-13 – 2022-02-04-342,9000.00pt——
Capital Research and Management Company2021-12-07 – 2022-02-04-14,130,511−0.73pt¥2,718.5¥2,409–2,968
キャピタル・インターナショナル株式会社2021-12-17 – 2022-02-02-4,398,200−0.24pt——

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4568/trades.

5% filings

Large shareholding reports on 4568
FiledFilerStakeChangeStated purpose
2026-10-21BlackRock Japan Co., Ltd.8.16%+0.19ptpure investment
2026-09-17BlackRock Japan Co., Ltd.7.97%+0.58ptpure investment
2026-02-06Capital Research and Management Company3.83%−1.95ptpure investment
2026-01-22Capital Research and Management Company5.78%−1.36ptpure investment
2025-12-22Nippon Life Insurance Company4.44%−1.04ptpure investment
2025-10-22Capital Research and Management Company7.14%+1.95ptpure investment
2025-09-19Sumitomo Mitsui Trust Asset Management Co.,Ltd.5.36%+0.21pt—
2025-09-05Mizuho Bank,Ltd.3.25%−1.78pt—
2025-08-07Mizuho Bank,Ltd.5.03%——
2025-05-22Mizuho Bank,Ltd.4.96%−0.31pt—

Cross-shareholdings

From the annual report's status of shareholdings
Listed strategic holdings
14 issues
Book value
¥36.0bn
Sold in the year
¥13.5bn 7 issues
Bought in the year
— — issues
Mutual, both reports
7
Held by listed cos.
19
HoldsBook valueShares vs. prior yearMutual
Shizuoka Financial Group, Inc. 5831¥14.0bn-11.1%both reports
Alfresa Holdings Corporation 2784¥9.0bn0.0%both reports
MEDIPAL HOLDINGS CORPORATION 7459¥8.0bn0.0%both reports
Cuorips Inc. 4894¥7.0bn0.0%no
TOHO HOLDINGS CO.,LTD. 8129¥6.3bn0.0%both reports
Ultragenyx Pharmaceutical Inc.¥4.2bn0.0%no
MS&AD Insurance Group Holdings, Inc. 8725¥2.7bn-49.1%both reports
Qol Holdings Co.,Ltd. 3034¥2.4bn0.0%no
Tokio Marine Holdings, Inc. 8766¥1.7bn-33.3%both reports
VITAL KSK HOLDINGS,INC. 3151¥1.5bn0.0%both reports

Held by: Shizuoka Financial Group, Inc. 5831, Iyogin Holdings,Inc. 5830, Otsuka Holdings Co., Ltd. 4578, MS&AD Insurance Group Holdings, Inc. 8725, Tokio Marine Holdings, Inc. 8766, MS&AD Insurance Group Holdings, Inc. 8725, MEDIPAL HOLDINGS CORPORATION 7459, Sompo Holdings, Inc. 8630, Hitachi, Ltd. 6501, NIHON NOHYAKU CO., LTD. 4997, TOHO HOLDINGS CO.,LTD. 8129, VITAL KSK HOLDINGS,INC. 3151 and 11 more

Purposes, all holdings and mutual flags via /v1/companies/4568/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2026-03-31
ShareholderSharesRatio
日本マスタートラスト信託銀行株式会社(信託口)312,068,00017.02%
株式会社日本カストディ銀行(信託口)128,365,0007.00%
日本生命保険相互会社71,095,0003.88%
STATE STREET BANK AND TRUST COMPANY 50500159,872,0003.26%
THE CHASE MANHATTAN BANK,N.A. LONDONSECS LENDING OMNIBUS ACCOUNT53,134,0002.90%
STATE STREET BANK AND TRUST COMPANY 50522333,388,0001.82%
JPモルガン証券株式会社33,322,0001.82%
JP MORGAN CHASE BANK 38578127,282,0001.49%
GOVERNMENT OF NORWAY24,025,0001.31%
株式会社静岡銀行22,422,0001.22%

U.S. funds holding 4568

SEC Form N-PORT, reports to 2026-07-31

316 U.S. funds held 230,668,666 shares worth $3.76bn.

FundSharesValue% of fundAs of
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND
VANGUARD STAR FUNDS
26,350,921$425.9m0.066%2026-07-31
VANGUARD HEALTH CARE FUND
VANGUARD SPECIALIZED FUNDS
22,675,166$366.5m0.960%2026-07-31
VANGUARD DEVELOPED MARKETS INDEX FUND
VANGUARD TAX-MANAGED FUNDS
17,465,509$280.8m0.089%2026-06-30
iShares Core MSCI EAFE ETF
iShares Trust
12,722,300$205.6m0.108%2026-07-31
MFS International Growth Fund
MFS SERIES TRUST X
10,906,700$184.9m0.802%2026-05-31

Up to 25 funds per stock via the API.

Get this as JSON

GET /v1/companies/4568
GET /v1/companies/4568/financials
GET /v1/companies/4568/details
GET /v1/companies/4568/segments
GET /v1/companies/4568/voting
GET /v1/companies/4568/tender-offers
GET /v1/companies/4568/indicators
GET /v1/companies/4568/earnings-releases
GET /v1/events?ticker=4568
GET /v1/companies/4568/trades         
GET /v1/companies/4568/cross-holdings 
GET /v1/companies/4568/brief          

Plans from $9 a month · Documentation